CARDIOVASCULAR DRUGS MARKET ANALYSIS

Cardiovascular Drugs MarketSize and Trends

According to American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths globally, representing 31% of all global deaths. The global number is expected to rise to 23.6 million by 2030. In 2010, the global burden of cardiovascular diseases was US$ 863 billion, and it is expected to rise to US$1044 billion by 2030. Around 2,200 U.S. citizens die due to cardiovascular diseases, everyday, which is one death in every 40 seconds. Moreover, coronary heart disease accounts for (45.1%) of the total cardiovascular disease, followed by stroke (16.5%), high blood pressure (9.1%), heart failure (8.5%), diseases related to arteries (3.2%), and other cardiovascular diseases in the U.S.

Global Cardiovascular Drugs Market Taxonomy

On the basis of drug class, the global cardiovascular drugs market is segmented into:

• Anti-Hypertensive
• Anti-Hyperlipidemics
• Anti-Coagulants
• Anti-Arrhythmic
• Anti-Fibrinolytic
• Others (antianginal drugs, cardiac glycosides, and anti-ischemic drugs)

On the basis of distribution channels, the global cardiovascular drugs market is segmented into:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Increasing R&D activities to launch new products is expected to support in growth of the cardiovascular drugs market